A Neuroscience-Based Nomenclature (NbN) for Psychotropic Agents.
作者信息
Frazer Alan, Blier Pierre
机构信息
Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas (Dr Frazer); Departments of Psychiatry and Cellular & Molecular Medicine, University of Ottawa, Ottawa, Canada (Dr Blier).
出版信息
Int J Neuropsychopharmacol. 2016 Aug 12;19(8). doi: 10.1093/ijnp/pyw066. Print 2016 Aug.
Abstract
摘要
相似文献
1
A Neuroscience-Based Nomenclature (NbN) for Psychotropic Agents.
Int J Neuropsychopharmacol. 2016 Aug 12;19(8). doi: 10.1093/ijnp/pyw066. Print 2016 Aug.
2
A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature.
Eur Neuropsychopharmacol. 2015 Dec;25(12):2318-25. doi: 10.1016/j.euroneuro.2015.08.019. Epub 2015 Sep 7.
3
Neuroscience-based nomenclature (NbN).
Lancet Psychiatry. 2017 Apr;4(4):272-273. doi: 10.1016/S2215-0366(17)30098-6.
4
A new nomenclature for classifying psychotropic drugs.
Br J Clin Pharmacol. 2017 Aug;83(8):1614-1616. doi: 10.1111/bcp.13302. Epub 2017 May 24.
5
Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications.
Eur Arch Psychiatry Clin Neurosci. 2016 Aug;266(5):385-6. doi: 10.1007/s00406-016-0699-0.
6
Neuroscience-based Nomenclature: What is it, why is it needed, and what comes next?
Psychiatry Clin Neurosci. 2018 Feb;72(2):50-51. doi: 10.1111/pcn.12615.
7
[Newly developed nomenclature (Neuroscience-based Nomenclature)].
Nihon Shinkei Seishin Yakurigaku Zasshi. 2016 Jun;36(3):69-71.
8
Naming for Psychotropic Drugs: Dilemma and Challenge.
Pharmacopsychiatry. 2017 Jan;50(1):1-2. doi: 10.1055/s-0042-119302. Epub 2017 Jan 24.
9
Classification of psychotherapeutic drugs.
J Psychosoc Nurs Ment Health Serv. 1981 Nov;19(11):15-7. doi: 10.3928/0279-3695-19811101-05.
10
Neuroscience-Based Nomenclature for Psychotropic Medication.
J Psychosoc Nurs Ment Health Serv. 2023 Jul;61(7):9-13. doi: 10.3928/02793695-20230607-02. Epub 2023 Jul 1.
引用本文的文献
1
Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.
Clin Drug Investig. 2024 Jul;44(7):471-493. doi: 10.1007/s40261-024-01377-9. Epub 2024 Jun 21.
2
Review: The use of functional magnetic resonance imaging (fMRI) in clinical trials and experimental research studies for depression.
Front Neuroimaging. 2023 Jun 27;2:1110258. doi: 10.3389/fnimg.2023.1110258. eCollection 2023.
3
The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.
Eur Arch Psychiatry Clin Neurosci. 2022 Jun;272(4):715-727. doi: 10.1007/s00406-021-01368-3. Epub 2022 Jan 6.
4
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.
Mol Psychiatry. 2022 Mar;27(3):1286-1299. doi: 10.1038/s41380-021-01381-x. Epub 2021 Dec 15.
5
The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.
Int J Neuropsychopharmacol. 2022 Feb 11;25(2):118-127. doi: 10.1093/ijnp/pyab066.
本文引用的文献
1
A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature.
Eur Neuropsychopharmacol. 2015 Dec;25(12):2318-25. doi: 10.1016/j.euroneuro.2015.08.019. Epub 2015 Sep 7.
2
Classifying psychotropic drugs by mode of action and not by target disorder.
CNS Spectr. 2013 Jun;18(3):113-7. doi: 10.1017/S1092852913000308.
3
Beyond psychoanaleptics - can we improve antidepressant drug nomenclature?
J Psychopharmacol. 2009 Jun;23(4):343-5. doi: 10.1177/0269881109105498.
4
Second W.D.M. Paton Memorial Lecture. The evolution of experimental pharmacology as a biological science: the pioneering work of Buchheim and Schmiedeberg.
Br J Pharmacol. 1995 Oct;116(4):2155-9. doi: 10.1111/j.1476-5381.1995.tb15047.x.
Zotero 插件